title: Efficacy and safety of telithromycin in community-acquired pneumonia.
abstract: Telithromycin, the first ketolide antibacterial, was developed for the treatment of community-acquired respiratory tract infections. This multicenter, open-label, uncontrolled study assessed the efficacy and safety of 800 mg, once-daily telithromycin in adults with community-acquired pneumonia (CAP). Based on bacteriologic eradication rates, telithromycin was shown to be effective for the treatment of CAP. Telithromycin was generally well tolerated, with gastro-intestinal adverse events observed most frequently (diarrhea 4/218 [1.8%], nausea 4/218 [1.8%], vomiting 5/218 [2.3%]). These results were consistent with those observed in randomized, active-controlled studies.
authors.affiliation: Drs Joynt, Venter and Associates, Medpark Center, Witbank, South Africa. lizmarie@mweb.co.za
authors.forename: Dirkie J
authors.initials: DJ
authors.lastname: Van Rensburg
authors.forename: Peter A
authors.initials: PA
authors.lastname: Matthews
authors.forename: Bruno
authors.initials: B
authors.lastname: Leroy
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D017714:Community-Acquired Infections / Q000188:drug therapy*; D005260:Female; D006801:Humans; D048628:Ketolides; D018942:Macrolides; D008297:Male; D008875:Middle Aged; D018410:Pneumonia, Bacterial / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D048628:Ketolides; D018942:Macrolides; C106791:telithromycin